Charles River Laboratories International (NYSE:CRL) Stock Rating Upgraded by Wall Street Zen

Charles River Laboratories International (NYSE:CRL) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other analysts have also recently weighed in on the stock. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a report on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Jefferies Financial Group upped their target price on shares of Charles River Laboratories International from $305.00 to $340.00 and gave the company a “buy” rating in a report on Monday, September 28th. Zacks Research downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 2nd. Finally, CLSA lowered shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $308.17.

Charles River Laboratories International Trading Up 0.1%

CRL opened at $337.91 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.12 and a current ratio of 1.41. Charles River Laboratories International has a one year low of $146.20 and a one year high of $379.63. The company has a market cap of $16.19 billion, a P/E ratio of 371.33, a PEG ratio of 3.05 and a beta of 1.36. The business’s 50-day simple moving average is $305.71 and its 200-day simple moving average is $225.19.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.12. The firm had revenue of $982.73 million during the quarter, compared to analysts’ expectations of $960.36 million. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The firm’s revenue was down 2.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.43 earnings per share. As a group, equities research analysts expect that Charles River Laboratories International will post 11.44 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon Parisotto sold 2,156 shares of the firm’s stock in a transaction that occurred on Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. This trade represents a 30.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares in the company, valued at approximately $10,080,038.70. This trade represents a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,566 shares of company stock valued at $23,149,288 in the last 90 days. Company insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently bought and sold shares of the business. Physician Wealth Advisors Inc. raised its holdings in shares of Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock worth $29,000 after acquiring an additional 55 shares during the last quarter. Continuum Advisory LLC purchased a new stake in shares of Charles River Laboratories International in the second quarter valued at $30,000. IFP Advisors Inc boosted its stake in shares of Charles River Laboratories International by 182.8% during the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 106 shares during the last quarter. Compass Wealth Management LLC acquired a new stake in shares of Charles River Laboratories International during the third quarter valued at $69,000. Finally, Activest Wealth Management increased its position in Charles River Laboratories International by 25.9% during the 3rd quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support.

The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions.